CPC Files Patent for Synthetic Sealant for Vascular Closure System (5/21/09)
In December 2008, CPC announced the addition of Olex Hnojewyj, Ph D. to its team of medical and research advisors, and in March 2009 the company announced a product development agreement with Dr. Hnojewyj. Today, CPC announces the filing of the first of several intellectual properties for formulations of synthetic sealant to be used in the MedClose VCS vascular closure product line, initially with 6-9Fr applications.
The MedClose VCS device consists of two parts: (1) A delivery system that delivers the sealant to the puncture site; and (2) the synthetic sealant itself. While CPC will continue to refine the MedClose VCS device commercially, the company is comfortable with its effectiveness as well as its proprietary and competitive advantages.